AAP
CCCC icon

Arax Advisory Partners’s C4 Therapeutics CCCC Stock Holding History

Arax Advisory Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89 Sell
19
-300
-94% -$1.03K ﹤0.01% 5143
2026
Q1 		$839 Buy
319
+300
+1,579% +$706 ﹤0.01% 3332
2025
Q4 		$36 Sell
19
-36
-65% -$85 ﹤0.01% 3974
2025
Q3 		$122 Buy
+55
New +$132 ﹤0.01% 3484

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's CCCC Position: Q2 2026 in Review

Arax Advisory Partners reduced its C4 Therapeutics (CCCC) stake by 94% in Q2 2026, selling an estimated $1.03K and leaving 19 shares worth $89. The position accounts for ﹤0.01% of the portfolio, ranked #5143.

Arax Advisory Partners first reported a position in CCCC in Q3 2025 and has held it in 4 quarters since. The position peaked at $839 in Q1 2026. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Arax Advisory Partners held 19 shares of C4 Therapeutics worth $89 as of Q2 2026.
  • Arax Advisory Partners sold 300 C4 Therapeutics shares in Q2 2026, an estimated $1.03K.
  • C4 Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5143 holding.
  • Arax Advisory Partners first reported a position in C4 Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's C4 Therapeutics position peaked at $839 in Q1 2026.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.